These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 33616313)

  • 1. A Step Ahead in Metastatic Renal Cell Carcinoma.
    Ravaud A
    N Engl J Med; 2021 Apr; 384(14):1360-1361. PubMed ID: 33616313
    [No Abstract]   [Full Text] [Related]  

  • 2. Immunotherapy and targeted-therapy combinations mark a new era of kidney cancer treatment.
    Zhang T; George DJ
    Nat Med; 2021 Apr; 27(4):586-588. PubMed ID: 33820997
    [No Abstract]   [Full Text] [Related]  

  • 3. Lenvatinib/everolimus improves survival better than everolimus alone in metastatic renal cell cancer.
    Clin Adv Hematol Oncol; 2015 Aug; 13(8):512-3. PubMed ID: 26351813
    [No Abstract]   [Full Text] [Related]  

  • 4. Novel Combination Shows Strong Antitumor Activity in Metastatic Renal Cell Carcinoma.
    Kahl KL
    Oncology (Williston Park); 2019 Dec; 33(12):. PubMed ID: 31914201
    [No Abstract]   [Full Text] [Related]  

  • 5. The Efficacy of Lenvatinib and Everolimus in Chromophobe-type Non-Clear-Cell Renal Cell Carcinoma: A Case Report and Literature Review.
    Schwartz C; Pfanzelter N; Kuzel TM
    Clin Genitourin Cancer; 2017 Oct; 15(5):e903-e906. PubMed ID: 28624319
    [No Abstract]   [Full Text] [Related]  

  • 6. Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trial.
    Motzer RJ; Hutson TE; Glen H; Michaelson MD; Molina A; Eisen T; Jassem J; Zolnierek J; Maroto JP; Mellado B; Melichar B; Tomasek J; Kremer A; Kim HJ; Wood K; Dutcus C; Larkin J
    Lancet Oncol; 2015 Nov; 16(15):1473-1482. PubMed ID: 26482279
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lenvatinib plus Pembrolizumab for Renal Cell Carcinoma.
    Hindié E
    N Engl J Med; 2021 Jul; 385(3):287. PubMed ID: 34260845
    [No Abstract]   [Full Text] [Related]  

  • 8. Lenvatinib plus Pembrolizumab for Renal Cell Carcinoma. Reply.
    Motzer R; Choueiri TK
    N Engl J Med; 2021 Jul; 385(3):287. PubMed ID: 34260846
    [No Abstract]   [Full Text] [Related]  

  • 9. Independent assessment of lenvatinib plus everolimus in patients with metastatic renal cell carcinoma.
    Motzer RJ; Hutson TE; Ren M; Dutcus C; Larkin J
    Lancet Oncol; 2016 Jan; 17(1):e4-5. PubMed ID: 26758760
    [No Abstract]   [Full Text] [Related]  

  • 10. Lenvatinib shows promise.
    Stone L
    Nat Rev Urol; 2015 Dec; 12(12):654. PubMed ID: 26526757
    [No Abstract]   [Full Text] [Related]  

  • 11. Combination therapy in kidney cancer: the next revolution?
    Buti S; Bersanelli M
    Lancet Oncol; 2015 Nov; 16(15):1441-1442. PubMed ID: 26482275
    [No Abstract]   [Full Text] [Related]  

  • 12. Lenvatinib in combination with everolimus in patients with advanced or metastatic renal cell carcinoma: A phase 1 study.
    Matsubara N; Naito Y; Nakano K; Fujiwara Y; Ikezawa H; Yusa W; Namiki M; Okude T; Takahashi S
    Int J Urol; 2018 Nov; 25(11):922-928. PubMed ID: 30129060
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hypertension Caused by Lenvatinib and Everolimus in the Treatment of Metastatic Renal Cell Carcinoma.
    Bendtsen MAF; Grimm D; Bauer J; Wehland M; Wise P; Magnusson NE; Infanger M; Krüger M
    Int J Mol Sci; 2017 Aug; 18(8):. PubMed ID: 28796163
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Major treatment improvements encourage kidney cancer researchers to seek further gains.
    Tuma RS
    J Natl Cancer Inst; 2008 Sep; 100(17):1202-3. PubMed ID: 18728277
    [No Abstract]   [Full Text] [Related]  

  • 15. A Systematic Review and Meta-analysis Comparing the Effectiveness and Adverse Effects of Different Systemic Treatments for Non-clear Cell Renal Cell Carcinoma.
    Fernández-Pello S; Hofmann F; Tahbaz R; Marconi L; Lam TB; Albiges L; Bensalah K; Canfield SE; Dabestani S; Giles RH; Hora M; Kuczyk MA; Merseburger AS; Powles T; Staehler M; Volpe A; Ljungberg B; Bex A
    Eur Urol; 2017 Mar; 71(3):426-436. PubMed ID: 27939075
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Second-line systemic therapy in metastatic renal-cell carcinoma: A review.
    Jain RK; Gandhi S; George S
    Urol Oncol; 2017 Nov; 35(11):640-646. PubMed ID: 28887097
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeted therapies in metastatic renal cancer in 2009.
    Bastien L; Culine S; Paule B; Ledbai S; Patard JJ; de la Taille A
    BJU Int; 2009 May; 103(10):1334-42. PubMed ID: 19338565
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Interdisciplinary recommendations for the treatment of metastatic renal cell carcinoma].
    Miller K; Bergmann L; Albers P; Gschwend J; Jäger E; Keilholz U
    Aktuelle Urol; 2010 May; 41(3):193-6. PubMed ID: 20486036
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Signaling inhibitors in metastatic renal cell carcinoma.
    Escudier B
    Cancer J; 2008; 14(5):325-9. PubMed ID: 18836338
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lenvatinib for the treatment of kidney cancer.
    Študentová H; Vitásková D; Melichar B
    Expert Rev Anticancer Ther; 2018 Jun; 18(6):511-518. PubMed ID: 29737893
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.